Clinica Chimica Acta最新文献

{"title":"Liquid chromatography-tandem mass spectrometry-based recalibration reduces inter-platform variability in aldosterone detection across chemiluminescence immunoassay platforms.","authors":"Jing Zhang, Baobin Luo, Zifu Fan, Xiaoyu Ma, Yungang Pu, Xiangyi Liu","doi":"10.1016/j.cca.2025.120604","DOIUrl":"https://doi.org/10.1016/j.cca.2025.120604","url":null,"abstract":"<p><strong>Background: </strong>Accurate aldosterone (ALD) measurement is vital in managing diseases such as primary aldosteronism (PA). However, inter-platform inconsistency across chemiluminescence immunoassay (CLIA) platforms complicates clinical decisions. This study conducted the largest comparison of CLIA platforms (six CLIA platforms) and one liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for ALD detection to date, systematically evaluated inter-platform consistency and explored the role of recalibration strategy based on LC-MS/MS in improving consistency among CLIA platforms.</p><p><strong>Methods: </strong>Fifty pooled clinical plasma samples were used to evaluate ALD levels across six different CLIA platforms and one LC-MS/MS assay. Friedman's test, Spearman correlation, Passing-Bablok regression, and Bland-Altman analysis were used to evaluate the consistency among assays. In addition, CLIA platforms were recalibrated against LC-MS/MS using regression equations with five pooled clinical plasma samples as calibration materials, and consistency was evaluated before and after recalibration.</p><p><strong>Results: </strong>LC-MS/MS yielded significantly lower ALD levels than six CLIA platforms (median: 120.75 vs. 129.29 to 216.25 pg/mL, P < 0.05). All assays correlated strongly (R ≥ 0.955), yet regression parameters revealed most slopes deviated from 1 (0.909 to 1.444) and intercepts ranged from -31.424 to 52.272 pg/mL. Bland-Altman plots demonstrated large relative mean differences (-2.396 % to 55.876 %) between assays. The recalibration process significantly reduced relative mean differences, whereas it showed limited improvement in addressing both proportional and systematic biases.</p><p><strong>Conclusions: </strong>These findings demonstrate that the consistency among CLIA platforms and LC-MS/MS assays is suboptimal. Actionable design strategies for developing recalibration coefficients, which reduce relative mean differences, are provided for CLIA platforms, emphasizing the necessity for standardized calibration to reduce inter-platform variability in clinical ALD measurement. The persistent proportional and systematic biases underscore the urgency for optimization in calibration strategy and detection methodology.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120604"},"PeriodicalIF":2.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145307124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"HbA1c: Gender & age differences in non-diabetic Saudi children & adults in Alqassim Buraidah region\" [Clin. Chim. Acta 558(Supplement 1) (2024) 118001].","authors":"A Alrashedi, Ghada M K Gaballah","doi":"10.1016/j.cca.2025.120648","DOIUrl":"https://doi.org/10.1016/j.cca.2025.120648","url":null,"abstract":"","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120648"},"PeriodicalIF":2.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145299002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticle-based liquid biopsy","authors":"Saja S. Falih ,&nbsp;Ahmed Mahdi Rheima ,&nbsp;Fatin Fadhel Al-Kazazz ,&nbsp;Zaid Nsaif Abbas","doi":"10.1016/j.cca.2025.120658","DOIUrl":"10.1016/j.cca.2025.120658","url":null,"abstract":"<div><div>Liquid biopsy has emerged as a revolutionary diagnostic strategy in oncology, providing a minimally invasive means for real-time monitoring of tumor dynamics through the analysis of circulating tumor-derived biomarkers in biological fluids. The incorporation of nanotechnology into liquid biopsy platforms has significantly enhanced analytical sensitivity and specificity by improving the detection and isolation of circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and exosomal non-coding RNAs. This review provides a detailed overview of recent advancements in nanoparticle-enabled liquid biopsy, focusing on essential nanomaterials, including gold nanoparticles (AuNPs), magnetic nanoparticles (MNPs), and silica nanoparticles, and their mechanistic contributions to enhancing assay performance through targeted biomarker capture, signal amplification, and multiplexed detection. The clinical translation of these technologies is exemplified by emerging platforms such as an exosome-based AuNPs-SERS–AI assay, which achieved an AUC of 0.97, with 90.2 % sensitivity and 94.4 % specificity in the detection of early-stage multi-cancer. Lastly, we outline future directions for the clinical integration of nanoparticle-assisted liquid biopsy, highlighting their potential to advance precision oncology through real-time, non-invasive, and personalized diagnostics.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120658"},"PeriodicalIF":2.9,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145299044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemical biosensing of Helicobacter pylori in gastrointestinal disease","authors":"Ghada Al-Assi ,&nbsp;Waleed K. Abdulsahib ,&nbsp;Sanan Thaer Abdal-Wahab ,&nbsp;G. Padma Priya ,&nbsp;Subhashree Ray ,&nbsp;J. Bethanney Janney ,&nbsp;Vipasha Sharma ,&nbsp;Ashish Singh Chauhan ,&nbsp;Zafar Aminov","doi":"10.1016/j.cca.2025.120660","DOIUrl":"10.1016/j.cca.2025.120660","url":null,"abstract":"<div><div><em>Helicobacter pylori</em> (<em>H. pylori</em>) infection remains a major global health concern and is closely linked to peptic ulcers, gastritis, and gastric cancer. Rapid, accurate, and noninvasive diagnostic tools are essential for early detection and effective management. This review explores the emerging role of electrochemical biosensors in the detection of <em>H. pylori</em>, highlighting their potential to revolutionize gastrointestinal diagnostics. By integrating biorecognition elements with advanced transduction mechanisms, electrochemical biosensors offer high sensitivity, specificity, and portability. We examine recent advances in sensor design, including nanomaterial-enhanced platforms and multiplexed detection strategies, and discuss their clinical applicability. Bridging the gap between laboratory innovation and clinical implementation, this work underscores the promise of electrochemical biosensing as a transformative approach from bench to bedside in the diagnosis of <em>H. pylori</em>-related diseases.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120660"},"PeriodicalIF":2.9,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic performance of a novel flow cytometry-based assay for the diagnosis of systemic lupus erythematosus","authors":"Yanling Zhao ,&nbsp;Minghua Zhan ,&nbsp;Jianing Chen ,&nbsp;Honglin Xu ,&nbsp;Futai Feng ,&nbsp;Zhou Bai ,&nbsp;Fang Wang ,&nbsp;Yongjing Cheng ,&nbsp;Xuan Zhang ,&nbsp;Yudong Liu","doi":"10.1016/j.cca.2025.120662","DOIUrl":"10.1016/j.cca.2025.120662","url":null,"abstract":"<div><h3>Objectives</h3><div>There is continuous need to identify novel biomarkers that can provide early and accurate diagnosis of systemic lupus erythematosus (SLE) due to its highly heterogenous nature and lack of specific clinical manifestations.</div></div><div><h3>Methods</h3><div>A total of 316 subjects comprising 127 patients with SLE, 129 patients with other autoimmune diseases as disease controls (DCs) and 60 healthy controls (HCs) were enrolled to determine the clinical relevance of the surface expression levels of CD169 on monocytes, CD317 on B cells and CD177 on neutrophils by flow cytometry for the diagnosis of SLE.</div></div><div><h3>Results</h3><div>The flow cytometric assay based on the combination of three molecules displayed a favorable diagnostic performance with an area under curve (AUC) of 0.9243. The sensitivities and specificities for this assay were 79.2 % and 96.2 % in the training cohort, and 82.1 % and 97.3 % in the validation cohort, respectively. Importantly, the diagnostic performance of this assay was independent of anti-double stranded DNA (dsDNA) antibodies with an AUC of 0.9329. The clinical performance of this assay was validated in an independent test cohort with a sensitivity and a specificity of 88.9 % and 95.9 %, respectively.</div></div><div><h3>Conclusion</h3><div>Our findings may have important clinical relevance in the diagnosis of SLE, especially when the suspects were tested negative for anti-dsDNA antibodies. Our study may shed light on a new direction other than detection of autoantibodies for the diagnosis of SLE in clinical settings.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120662"},"PeriodicalIF":2.9,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145299059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of plasma APOE4 with a novel automated Lumipulse immunoassay enables the identification of homozygous and heterozygous APOE ε4 carrier status","authors":"G. Musso ,&nbsp;C. Cosma ,&nbsp;S. Moz ,&nbsp;C. Gabelli ,&nbsp;F. Navaglia ,&nbsp;A. Codemo ,&nbsp;C.F. Zambon ,&nbsp;A. Cagnin ,&nbsp;A. Antonini ,&nbsp;M. Corbetta ,&nbsp;M. Montagnana","doi":"10.1016/j.cca.2025.120659","DOIUrl":"10.1016/j.cca.2025.120659","url":null,"abstract":"<div><h3>Introduction</h3><div>The Apolipoprotein E (APOE) ε4 allele is a significant risk factor for Alzheimer's disease (AD). While genetic testing remains the gold standard for determining <em>APOE</em> status, protein-level quantification could offer advantages in clinical practice. This study evaluates a novel, fully automated immunoassay for quantifying APOE4 and total APOE (Pan-APOE) in plasma samples, assessing its accuracy and clinical utility compared to traditional genetic testing.</div></div><div><h3>Materials and methods</h3><div>Plasma samples from 65 patients (39 ε4 non-carriers, 21 ε4 heterozygous, 5 ε4 homozygous) were analyzed using the Lumipulse 1200 G APOE4 &amp; Pan-APOE immunoassays. The APOE4/Pan-APOE ratio (Ratio%) was calculated to determine ε4 carrier status. Results were compared to genetic testing. Assay repeatability was evaluated using triplicate measurements from three patients with different genotypes.</div></div><div><h3>Results</h3><div>APOE4 and Pan-APOE protein levels and Ratio% differed significantly across ε4 status groups (<em>p</em> &lt; 0.0001). The Ratio% showed no overlap between groups. ROC curve analysis for ε4 carrier identification showed an AUC of 1.00, with 100 % sensitivity and specificity at a 14 % cut-off. Perfect agreement was observed between the immunoassay and genetic testing (Cohen's kappa = 1.00, <em>p</em> &lt; 0.0001). Intra-assay CV was &lt;5 % for APOE4 and &lt;8 % for Ratio%.</div></div><div><h3>Discussion</h3><div>This novel immunoassay demonstrates excellent and potential for faster results could offer advantages in clinical practice, particularly for AD therapy eligibility evaluation. However, further validation in larger, diverse cohorts is necessary before considering widespread clinical implementation.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120659"},"PeriodicalIF":2.9,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke biomarkers: the promise of point-of-care testing","authors":"Fahad Alsaikhan","doi":"10.1016/j.cca.2025.120654","DOIUrl":"10.1016/j.cca.2025.120654","url":null,"abstract":"<div><div>Stroke remains a leading cause of disability and mortality requiring rapid and accurate diagnostic tools to improve patient outcomes. Biomarkers such as N-terminal pro B-type natriuretic peptide (NT-proBNP), glial fibrillary acidic protein (GFAP), C-reactive protein (CRP), S100B, neurofilament light chain (NfL), and microRNAs have been introduced as promising indicators for early stroke detection, subtype differentiation, and prognosis. However, typical laboratory-based assays are time-consuming and lack the portability required for emergency settings. Recent advances in biosensor technologies, including electrochemical, optical, and nanomaterial-based platforms, offer transformative potential for point-of-care (POC) stroke diagnosis. These biosensors enable ultrasensitive, rapid, and cost-effective detection of stroke biomarkers, facilitating timely clinical decision-making. This review first focuses on blood biomarkers related to ischemic stroke, including protein and RNA based biomarkers and other relevant molecules. Then, it summarizes the latest optical, and electrochemical bio-sensing techniques for the detection of critical biomarkers in stroke. Finally, we discuss analytical performance and advances in biosensor technology for use in POC devices. By providing a wide-ranging discussion on the stroke biomarkers and current state of biosensor approaches for stroke detection, this review aims to highlight the importance of these devices in improving patient outcomes and progressing stroke-based studies.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120654"},"PeriodicalIF":2.9,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving self-collected dried blood spot specimens for phenylketonuria monitoring: a 10-year computer vision review of dried blood spot specimen quality","authors":"Nick Flynn ,&nbsp;Stuart J. Moat ,&nbsp;Sarah L. Hogg","doi":"10.1016/j.cca.2025.120656","DOIUrl":"10.1016/j.cca.2025.120656","url":null,"abstract":"<div><h3>Background</h3><div>Biochemical monitoring of phenylketonuria (PKU) is performed using dried blood spot (DBS) specimens, usually collected by the patient or carer. DBS quality affects DBS phenylalanine results and self-collected specimen quality may often be sub-optimal. However, it is unclear how often specimen quality affects clinical interpretation of PKU monitoring results, or whether sustained improvements in DBS quality are achievable in this setting.</div></div><div><h3>Methods</h3><div>We used a computer vision algorithm to objectively assess DBS quality in 8472 DBS specimens collected from 111 PKU patients over a 10-year period. Trends in specimen quality were analysed over time, by patient, and by frequency of specimen collection. We modelled the effect of sub-optimal DBS size on phenylalanine result classification against European PKU treatment guidelines.</div></div><div><h3>Results</h3><div>The proportion of poor-quality DBS decreased from 66.5 % to 3.2 % over a 10-year period. The median proportion of acceptable specimens returned by each patient each year improved from 28.6 % in 2015/16 to 100 %. Patients returning specimens more frequently showed better DBS quality performance, with acceptability rates of 96.3 % in patients who returned ≥10 specimens in 2024–25, compared to 78.3 % in patients who returned &lt;5 specimens. Improvement in DBS quality reduced potential misclassification against PKU treatment guidelines due to DBS size from 3.1 % to 0.6 %.</div></div><div><h3>Conclusions</h3><div>Without training and education, DBS quality in self-collected specimens may be very poor. However, substantial improvements are achievable for PKU monitoring specimens, reducing total measurement error and the risk of incorrect clinical interpretation of results.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120656"},"PeriodicalIF":2.9,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemical biosensors for inflammatory bowel disease","authors":"Mukhabbat Saidova ,&nbsp;Nargiza Xamrakulova ,&nbsp;Nodira Mirzayeva ,&nbsp;Ilnur Аbitov ,&nbsp;Firuza Turayeva ,&nbsp;Barno Shagazatova ,&nbsp;Gulchekhra Bekenova ,&nbsp;Maxmudjon Butaboyev ,&nbsp;Islom Kadirov ,&nbsp;Bunyod Kendjaev ,&nbsp;Bakhtiyor Khasanov ,&nbsp;Nigora Dustova ,&nbsp;Kurbaniyazova Madina Zafajanovna","doi":"10.1016/j.cca.2025.120651","DOIUrl":"10.1016/j.cca.2025.120651","url":null,"abstract":"<div><div>Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic and increasingly prevalent condition characterized by gastrointestinal inflammation and a substantial clinical burden. While conventional diagnostic modalities such as endoscopy and histopathology remain essential, their invasiveness and limited suitability for continuous monitoring underscore the need for innovative, patient-friendly approaches. Electrochemical biosensors have emerged as transformative tools for noninvasive and minimally invasive IBD detection, offering rapid, sensitive, and matrix-flexible analysis of key biomarkers in blood, sweat, stool, and urine. This review presents a comprehensive overview of recent advancements in electrochemical biosensor technology for the noninvasive detection of IBD. It explores cutting-edge developments in biorecognition elements, transducer configurations, signal amplification techniques, and detection modalities. These innovations collectively demonstrate the transformative potential of electrochemical biosensors to reshape IBD diagnostics, enabling personalized, real-time monitoring and paving the way for more accessible, patient-centered disease management.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120651"},"PeriodicalIF":2.9,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are frequent calibrations enough? A patient-based quality control perspective on blood gas and laboratory analyzers","authors":"Coskun Cavusoglu","doi":"10.1016/j.cca.2025.120649","DOIUrl":"10.1016/j.cca.2025.120649","url":null,"abstract":"<div><h3>Objectives</h3><div>Quality control (QC) plays a fundamental role in clinical laboratories by safeguarding the accuracy and reliability of test outcomes. Conventional QC materials often fail to fully reflect patient sample behavior due to matrix differences, leading to non-commutability. Patient-Based Quality Control (PBQC), which evaluates real patient data, offers greater sensitivity for detecting analytical errors. Blood gas analyzers in point-of-care settings rely on frequent automatic calibrations, whereas central laboratory analyzers use operator-driven calibrations. This study compared their analytical performance using PBQC metrics.</div></div><div><h3>Methods</h3><div>In this retrospective study, patient results for glucose, sodium (Na), and hemoglobin (Hgb) were collected over a three-month period (May–July) at Ümraniye Training and Research Hospital. Data were obtained from central laboratory analyzers (Roche COBAS 8000, Mindray BC6000) and a point-of-care blood gas analyzer (Siemens Rapidpoint 500). A total of 112,898 results were included following the application of three truncation methods based on Reference Interval (RI), RCVG, and the Outlier Q test. PBQC analysis was conducted using Exponentially Weighted Moving Average (EWMA) charts (λ = 0.05) with evaluation of False Positive Flag Rate and average number of patient results before error detection (ANPed), in accordance with IFCC recommendations. Probability of error detection (Ped) values were also calculated from IQC data.</div></div><div><h3>Results</h3><div>PBQC analysis demonstrated that the False Positive Flag Rate was consistently lower in central laboratory analyzers compared to the blood gas analyzer. ANPed values were low in both device types, indicating effective error detection capability. Ped values reached 1.00 for glucose in the Rapidpoint analyzer and sodium in the COBAS 8000, whereas lower Ped values were observed for Rapidpoint sodium and hemoglobin.</div></div><div><h3>Conclusions</h3><div>PBQC provides an effective complement to conventional QC, enabling early detection of analytical deviations in both central laboratory and point-of-care analyzers. Our findings show that blood gas analyzers, despite frequent automatic calibrations, generate more false positive alerts, whereas central laboratory analyzers demonstrate more stable performance. We propose that PBQC-based algorithms be integrated into blood gas analyzer software, allowing calibrations to be triggered by observed deviations rather than fixed time intervals. Such an approach would enhance analytical reliability and improve quality assurance in point-of-care testing.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120649"},"PeriodicalIF":2.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}